en

Dual Trend presents MilliExo Vet® at the SIVE 2025 Congress: a new frontier in equine regenerative medicine

27/11/2025

Dual Trend at the SIVE 2025 Congress

During the congress, at the Dual Trend stand, veterinarians and specialists will have the opportunity to explore the technology firsthand, assess its clinical use and delve into the new protocols dedicated to equine regenerative medicine.

MilliExo Vet® introduces to the veterinary field an advanced, safe and scientifically supported solution designed to enhance performance and recovery in sport horses.

Dual Trend participates in the SIVE 2025 Congress presenting MilliExo Vet®, the new autologous exosomal system designed for regenerative medicine in horses.
The protocol, derived from the MilliExo® technology, enables the production of a suspension rich in adipose-derived mesenchymal stromal cells (MSCa), pericytes and active exosomes in just 45 minutes, without centrifugation or enzymes.

Discover MilliExo Vet®

An innovative system dedicated to animal regenerative medicine, with applications in:

  • Equine and canine orthopaedics and traumatology

  • Post-traumatic tissue regeneration

  • Tendon and joint repair

  • Optimisation of functional recovery times

MilliExo Vet was developed through collaboration between Dual Trend, Italian university centres and international veterinary specialists, following a One Health approach that integrates human and veterinary regenerative research.

Why MilliExo Vet ® is innovative

During the congress, Dual Trend will present its flagship scientific platforms:

MilliExo® and MilliExo Lab® — the integrated system for harvesting and activating autologous exosomes from adipose tissue.
The protocol, based on controlled hypoxia and physiological temperature at 37 °C, makes it possible to obtain a suspension rich in exosomal markers (CD9, CD63, CD81, Alix, HSP70) with high regenerative potential.

MilliGraft® — the patented mechanical microfiltration kit for adipose tissue, capable of isolating vital mesenchymal cells (>99%) and CD34⁺/CD146⁺ sub-populations, the foundation of all Dual Trend protocols.

Both systems are medical devices compliant with Regulation (EU) 2017/745 (MDR), ensuring quality, safety and full traceability.

Share